U.K. regulators call out AstraZeneca ad

AstraZeneca failed to accurately reflect the side effects of its top-selling antipsychotic drug Seroquel in an advertisement to doctors, a U.K. regulatory panel has ruled. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.